Story
Volkswagen's Fortunes Tied to EU Trade Policy on China, Citi Says

Summary
Citi analysts maintained a Buy rating on Volkswagen but warned the automaker's stock performance over the next year hinges on potential EU trade protection against Chinese EV competition, following a recent profit warning.
Volkswagen's stock performance over the next 12 months will largely depend on potential European Union trade protection measures against mounting competition from Chinese automakers, according to analysts at Citi. The bank maintained its Buy rating and €100 price target on the German carmaker, but highlighted the trade issue as the key variable for investors moving forward.
Estimates Slashed After Profit Warning
The analysis follows a profit warning issued by Volkswagen late last week. In response, Citi revised its financial model, citing pressures related to China, increased competition from Chinese brands in Europe, and margin dilution from battery-electric vehicles (BEVs).
Citi's updated forecasts include:
- A €1 billion deterioration in 2026 operating performance at the VW Core and Audi brands.
- An additional €8.5 billion in exceptional costs factored in for the third quarter of 2026.
- A significant cut to earnings-per-share (EPS) estimates, now projecting a loss of €3.36 for 2026, followed by earnings of €8.55 in 2027 and €20.15 in 2028.
Analysts noted their own 2026 downgrade was less severe than the company's guidance cut, as their previous estimates were already at the low end of the prior range. The bank also incorporated an assumed timeline for Volkswagen's announced €10 billion restructuring program.
'Worst-Case' Scenario Priced In
AdDespite the sharp cuts to earnings projections, Citi kept its price target unchanged, pointing to minimal changes in its underlying earnings and free cash flow forecasts. Analysts argued that Volkswagen's current share price already reflects a "worst-case VW outcome" across all its segments, giving no credit for potential savings from restructuring or asset disposals.
Citi forecasts the automaker's free cash flow will gradually improve to over €6 billion, supported by solid underlying earnings and cuts to capital expenditure and R&D spending. However, the bank also sharply reduced its dividend assumptions due to the new charges and what it called a volatile "'payout ratio' dividend policy," suggesting a more consistent approach would better serve investors.
Market and Investor Impact
For investors, Citi's note frames the key risk and potential catalyst for Volkswagen stock. The automaker's exposure to competition from Chinese EV manufacturers is a major headwind, but any protective trade measures enacted by the EU could provide significant relief and a positive catalyst for the shares.
The firm flagged Volkswagen's pattern of negative Friday-afternoon announcements and earnings volatility as ongoing investment risks. The ultimate performance of the stock, however, is seen as being closely linked to the geopolitical and trade policy landscape in the coming year.
Read next
More on Stocks
Ryanair Rules Out Fuel Surcharges, CEO Predicts Pressure on Rivals
Ryanair will not add fuel surcharges despite rising jet fuel prices, a move CEO Michael O’Leary said will pressure competitors and could accelerate industry consolidation in Europe.

Deutsche Bank Shares Fall After CFO Warns on Investment Banking Revenue
Shares of Deutsche Bank declined over 4% after its Chief Financial Officer signaled that third-quarter investment banking revenue could be flat or slightly below the prior year, overshadowing positive metrics in other divisions.

D-Wave Quantum Stock Gains on Strategic Partnership with IT Firm CGI
Shares of D-Wave Quantum Inc. (QBTS) rose in premarket trading after the company announced a strategic partnership with global IT and business consulting giant CGI (GIB) to develop and commercialize quantum computing applications for enterprise clients.

Oruka Therapeutics Falls 5% Despite Positive Phase 2a Psoriasis Drug Data
Shares of the biotechnology company declined even as it reported improved efficacy for its psoriasis treatment, ORKA-001, in a 28-week mid-stage clinical trial.